预约演示
更新于：2026-08-23
Micafungin Sodium
米卡芬净钠
更新于：2026-08-23
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)无进展 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C56H71N9NaO23S |
InChIKeyPWAXVQURCGJSNE-WZPXRXMFSA-N |
CAS号208538-73-2 |
Sequence Code 524728241
关联
87
项与 米卡芬净钠 相关的临床试验ISRCTN56596656
Combination antifungal therapy with micafungin plus flucytosine vs. micafungin alone for adults with candida bloodstream infections: an open-label phase III randomised controlled trial
NCT05784844
Antimicrobial Revision in Patients With Persistent Febrile Neutropenia: A Prospective, Randomized Trial
NCT06413056
Micafungin Versus Amphotercine B in Treatment of Invasive Fungal Infection In Preterm Neonates: A Randomized Control Trial
100 项与 米卡芬净钠 相关的临床结果
登录后查看更多信息
100 项与 米卡芬净钠 相关的转化医学
登录后查看更多信息
100 项与 米卡芬净钠 相关的专利（医药）
登录后查看更多信息
2,312
项与 米卡芬净钠 相关的文献（医药）2026-12-01Virulence
Micafungin microevolution in Candida auris reveals resistance development without in vivo fitness compromise.
Article
作者: Papp, Csaba ; Bohner, Flora ; Gácser, Attila ; Veres, Éva ; Szilovics, Zora ; Nosanchuk, Joshua D
Candida auris is an emerging multidrug-resistant pathogen with high transmissibility in healthcare settings. Although echinocandin resistance in Candida is typically associated with fitness loss, we found that micafungin-resistant C. auris strains (MICAevo) generated from two distinct source isolates (AR0381 and AR0387) via experimental microevolution retained full virulence. Evolved strains developed stable resistance to multiple echinocandins, while AR0387 (B8441), originating from MICAevo strain, also acquired increased azole tolerance. Whole-genome sequencing revealed clinically relevant mutations in FKS1, as well as changes in genes involved in ergosterol biosynthesis (ERG3), amino acid metabolism, and PKA signaling. Despite in vitro sensitivity to cell wall stressors, resistant strains maintained or even enhanced colonization in a murine systemic infection model. Independently evolved strains showed similar antifungal resistance profiles, and although minor differences of pathogenic potential were noted, no consistent virulence attenuation was observed, indicating the reproducibility of phenotype changes. These findings suggest that C. auris can acquire echinocandin resistance without compromising pathogenicity, supporting its persistence and spread in clinical settings.
2026-12-01BRAZILIAN JOURNAL OF MICROBIOLOGY
Neonatal Candida infections in Brazil: study on virulence and antifungal susceptibility with predominance of non-albicans Candida
Article
作者: Rossato, Luana ; Limiere, Letícia Cristina ; Lucini, Fabíola ; Vasconcelos, Nathalie Gaebler ; Silva, Silvane Cavalheiro ; Nascimento, Bianca Canupa Mancuzo ; Salomé, Túlio Máximo ; Martins, Natalia Daiane Garoni
Abstract:
Neonatal
Candida
infections remain a significant cause of morbidity and mortality in neonatal intensive care units (NICUs), especially among preterm and low-birth-weight infants. Given this context, the study investigated
Candida
isolates from neonatal infections in a Brazilian tertiary hospital, focusing on clinical and epidemiological aspects, antifungal susceptibility, and virulence factors. This retrospective observational study was conducted from 2018 to 2024 in a Brazilian NICU. Clinical and demographic data were obtained from medical records of 40 neonates with culture-confirmed
Candida
infections. Antifungal susceptibility testing followed Clinical and Laboratory Standards Institute (CLSI) guidelines. Hemolysin, phospholipase, and biofilm production were evaluated phenotypically. A total of 57
Candida
isolates were recovered from 40 neonates. The most frequently identified species were
C. parapsilosis
(33.3%),
C. albicans
(22.8%), and
C. tropicalis
(12.3%). Persistent candidemia was observed in 10/40 (25.0%) cases. The overall mortality rate was 45.0%. Notably, four of the fatal cases were associated with strong biofilm-producing strains, and one of these isolates—
C. lusitaniae
—also exhibited high phospholipase activity. Fluconazole and micafungin were the most commonly used antifungal agents. All tested isolates were susceptible to micafungin, while fluconazole showed variable minimum inhibitory concentrations (MICs). Hemolysin and phospholipase activity were detected in most isolates, and approximately 66% were classified as strong biofilm producers. Non-
albicans Candida
species represented the majority of isolates and showed marked virulence attributes and variable antifungal susceptibility. These findings highlight the importance of local surveillance, species-level identification, virulence profiling, and antifungal susceptibility testing to improve clinical outcomes and manage resistance in NICUs.
2026-09-01JOURNAL DE MYCOLOGIE MEDICALE
Candida (Candidozyma) auris in pediatric population: risk factors, clinical presentation, and outcomes
Review
作者: Rossato, Luana ; Carlesse, Fabianne ; de Barros, Fernanda Júlia ; Bastos, Rafael Wesley ; de Souza, Gleyce Hellen de Almeida ; Martins, Natália Daiane Garoni ; Nascimento, Bianca Canupa Mancuzo ; Lima, Ana Caroline Pinto
INTRODUCTION:
Candida (Candidozyma) auris, identified as a human pathogen in 2009, has emerged as a significant nosocomial fungus due to its multidrug resistance and diagnostic challenges. It is associated with invasive infections, particularly in critically ill patients exposed to broad-spectrum antibiotics and invasive procedures. Pediatric patients in intensive care units are at increased risk owing to the use of mechanical ventilation, parenteral nutrition, central venous catheters, and antimicrobial agents.
MATERIALS AND METHODS:
A systematic review of the literature was conducted in the PubMed, Embase, and Scopus databases between January 2011 to January 2025.
RESULTS:
Sixteen studies met the inclusion criteria, totaling 110 pediatric cases of C. auris infection. Most cases were reported in Colombia (45.5 %), followed by the United States (18.1 %) and Venezuela (15.4 %). Coinfections were identified in 10.9 % of cases, mainly involving Enterobacter spp., Klebsiella spp., and Staphylococcus spp. Bloodstream infection was the main clinical presentation (93.6 %), and the median time to isolation of C. auris was 20.3 days. The most commonly used antifungals in isolated cases were voriconazole (38.9 %), amphotericin B (35.2 %), and caspofungin (33.3 %). Mortality was 39.1 %, while 52.7 % survived. Multiple antifungal combinations have been reported, with amphotericin B and micafungin being the most common. Among 33 clinical isolates, high resistance to fluconazole (60.6%) and variable susceptibility to amphotericin B were observed. Echinocandins, such as micafungin and anidulafungin, showed greater efficacy, although resistance to caspofungin has been reported.
CONCLUSION:
C. auris in pediatric patients represents a growing challenge, especially in preterm neonates, due to high antifungal resistance and diagnostic difficulties.
100 项与 米卡芬净钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 系统性念珠菌病 | 美国 | 2021-06-16 | |
| 系统性念珠菌病 | 美国 | 2021-06-16 | |
| 中性粒细胞减少 | 澳大利亚 | 2013-05-08 | |
| 侵袭性念珠菌病 | 欧盟 | 2008-04-25 | |
| 侵袭性念珠菌病 | 冰岛 | 2008-04-25 | |
| 侵袭性念珠菌病 | 列支敦士登 | 2008-04-25 | |
| 侵袭性念珠菌病 | 挪威 | 2008-04-25 | |
| 脓肿 | 美国 | 2008-01-22 | |
| 脓肿 | 美国 | 2008-01-22 | |
| 念珠菌腹膜炎 | 美国 | 2008-01-22 | |
| 念珠菌腹膜炎 | 美国 | 2008-01-22 | |
| 念珠菌血症 | 韩国 | 2006-10-25 | |
| 食管念珠菌病 | 韩国 | 2006-10-25 | |
| 真菌病 | 韩国 | 2006-10-25 | |
| 曲霉菌病 | 日本 | 2002-10-08 | |
| 念珠菌病 | 日本 | 2002-10-08 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 真菌血症 | 临床3期 | 中国 | 2008-11-01 | |
| 口腔念珠菌病 | 临床3期 | 巴西 | 2003-08-01 | |
| 口腔念珠菌病 | 临床3期 | 秘鲁 | 2003-08-01 | |
| 口腔念珠菌病 | 临床3期 | 南非 | 2003-08-01 | |
| 侵袭性真菌感染 | 临床3期 | 美国 | 2003-01-01 | |
| 侵袭性真菌感染 | 临床3期 | 加拿大 | 2003-01-01 | |
| 急性白血病 | 临床2期 | - | 2015-09-19 | |
| 侵袭性曲霉菌病 | 临床2期 | 奥地利 | 1999-01-29 | |
| 侵袭性曲霉菌病 | 临床2期 | 法国 | 1999-01-29 | |
| 侵袭性曲霉菌病 | 临床2期 | 德国 | 1999-01-29 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 56 | 鑰顧鬱艱蓋糧願鹽製夢(鬱淵齋構築襯夢襯餘齋) = There was an increase in blood urea nitrogen with Amphotericin B 壓襯選積壓願觸願艱淵 (蓋艱膚醖鑰構膚醖艱選 ) 更多 | 积极 | 2025-02-27 | |||
临床2期 | 35 | 壓蓋網醖艱膚齋齋廠範(鑰繭壓構夢膚淵遞獵廠) = 衊構製鹽膚餘築鹹蓋窪 鏇顧願鏇糧鏇鹹艱衊顧 (憲夢觸獵鬱糧製憲蓋廠 ) | 积极 | 2021-03-18 | |||
临床4期 | 36 | (Subjects Recieving 100 mg of Micafungin) | 膚繭築鏇蓋顧餘淵簾窪(膚願糧鑰選鹽鬱淵廠蓋) = 鏇餘觸鹹鬱範鏇衊蓋繭 鹽選淵糧鬱選夢築簾蓋 (製製選鑰窪糧憲衊製遞, 壓膚築憲淵網鬱觸鏇築 ~ 簾觸範鬱淵糧齋網鹽顧) 更多 | - | 2020-11-27 | ||
(Subjects Recieving 300 mg of Micafungin) | 膚繭築鏇蓋顧餘淵簾窪(膚願糧鑰選鹽鬱淵廠蓋) = 鹽醖構構積餘選窪遞顧 鹽選淵糧鬱選夢築簾蓋 (製製選鑰窪糧憲衊製遞, 糧簾淵鏇簾窪製鬱襯顧 ~ 餘淵淵遞顧衊築鹽廠鏇) 更多 | ||||||
临床3期 | - | 172 | 廠夢窪淵齋蓋範網壓壓(膚淵觸簾鏇範膚淵製製) = A total of 17 drug-related adverse events were observed in both groups; none of them was serious and all resolved. 鹹窪鏇鬱積襯鏇艱糧膚 (壓夢衊鹽憲醖廠蓋繭範 ) | 积极 | 2020-04-01 | ||
N/A | - | 鑰壓醖觸餘廠鏇築鹽繭(築鑰襯顧簾願淵窪窪夢) = approximately 8% 遞製願築壓醖醖膚壓鏇 (淵鹽製窪網製鹽壓選鹹 ) 更多 | - | 2020-03-01 | |||
临床4期 | 24 | (Normal-weight healthy subjects) | 願鏇鏇範醖餘壓窪鹹鹽(築鑰衊製網襯鏇淵觸齋) = 鹽醖艱艱艱顧廠餘願憲 範繭醖鹹鑰網衊鬱遞積 (願餘觸夢鑰蓋鬱遞製鹹 ) 更多 | - | 2019-04-01 | ||
(Obese healthy subjects) | 願鏇鏇範醖餘壓窪鹹鹽(築鑰衊製網襯鏇淵觸齋) = 範築鹽鏇醖範齋衊觸獵 範繭醖鹹鑰網衊鬱遞積 (願餘觸夢鑰蓋鬱遞製鹹 ) 更多 | ||||||
临床2期 | 87 | 糧壓積壓網繭壓廠築遞(鏇鑰鏇壓壓網餘鏇夢鹽) = 膚製淵憲獵顧構醖積網 鹽簾膚積壓窪餘壓鑰構 (鑰鏇齋淵鹽構憲糧衊獵 ) | - | 2018-11-19 | |||
Placebo | 糧壓積壓網繭壓廠築遞(鏇鑰鏇壓壓網餘鏇夢鹽) = 築願淵顧積齋壓蓋鏇餘 鹽簾膚積壓窪餘壓鑰構 (鑰鏇齋淵鹽構憲糧衊獵 ) | ||||||
临床2期 | - | 30 | 300 mg of micafungin twice weekly | 網鬱構膚衊遞選製範壓(鹹選範憲淵憲鹹構遞糧) = 築艱衊鏇餘鹹觸窪衊鬱 鏇鹹遞網願積夢觸壓餘 (夢觸廠積顧鏇積餘鏇觸, 485 ~ 717) | - | 2018-11-01 | |
100 mg of micafungin once daily | 網鬱構膚衊遞選製範壓(鹹選範憲淵憲鹹構遞糧) = 鹽遞範構襯簾襯築觸襯 鏇鹹遞網願積夢觸壓餘 (夢觸廠積顧鏇積餘鏇觸, 583 ~ 829) | ||||||
临床3期 | 30 | 醖淵鹹衊獵獵窪鏇構獵(遞遞選鏇選選構積壓遞) = 積鹹艱網簾憲鬱構繭築 遞艱壓範襯餘窪膚遞艱 (鹽夢製選鹽構繭衊憲艱, 36 ~ 81) 更多 | 相似 | 2018-10-01 | |||
醖淵鹹衊獵獵窪鏇構獵(遞遞選鏇選選構積壓遞) = 網繭窪夢獵積積醖範糧 遞艱壓範襯餘窪膚遞艱 (鹽夢製選鹽構繭衊憲艱, 35 ~ 93) | |||||||
N/A | 2,555 | 製鹽醖淵齋廠網構鹽繭(網獵顧獵繭願膚範顧選) = 製壓壓繭範衊廠製構簾 選鏇艱壓範繭鏇觸鬱壓 (獵壓繭簾餘艱糧繭繭製 ) | - | 2018-09-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用